Background: Amino acid (aa) substitutions in genotype 1 HCV core region (HCV-CR) serve as a negative predictor of treatment responses in Japanese chronic hepatitis C (CHC) patients. Whether this phenomenon could be extrapolated to non-Japanese patients remains unclear. We evaluated the effect of aa substitutions in HCV-CR on clinicopathological features and treatment responses in Taiwanese patients. Methods: Clinical and serial virological data were collected from 147 consecutive Taiwanese HCV genotype 1 patients who received pegylated interferon plus ribavirin therapy. Quantification of HCV RNA and sequences of HCV-CR were determined by molecular methods. Results: Of 147 patients, 90 (61.2%) attained rapid virological response (RVR) and 97 (66.0%) attained sustained virological response (SVR). Patients without aa substitutions in HCV-CR (coreWW) had a higher SVR than those with both aa70 and aa91 substitutions (coreMM; 70.5% versus 45.0%; P=0.039). Moreover, coreMM was associated with a higher γ-glutamyl transpeptidase level (P=0.026) as well as more severe liver fibrosis (P=0.027) than coreWW, and patients with aa70 substitution (coreMW) were associated with more severe liver steatosis and fibrosis than those without (P=0.020 and P=0.002, respectively). In multivariate analyses, lower pretreatment body mass index, milder liver fibrosis, 48 weeks of treatment and RVR, but not aa substitutions in HCV-CR, predicted a higher SVR rate. Conclusions: Although aa substitution in genotype 1 HCV-CR is associated with more severe liver fibrosis and might be a negative predictor of SVR in Taiwanese CHC patients with interferon-based therapy, RVR and other clinical factors outweigh its role in predicting SVR.
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HCV infection is the major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma worldwide [1, 2] . Pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy is the current standard of care for the treatment of chronic hepatitis C (CHC) and can cure the disease by attaining a sustained virological response (SVR; defined as undetectable serum HCV RNA level 24 weeks off therapy) [3] . However, combination therapy is still expensive, has many unpleasant side effects, and is not effective in a certain proportion of CHC patients [4] . For example, the SVR rate of HCV genotype 1 (HCV-1) infection, the major genotype worldwide, is approximately 70% in Asian patients compared with 50% in Caucasian patients [5] [6] [7] . Therefore, identifying predictors of SVR in patients with HCV-1 infection is important in terms of increasing efficacy, avoiding unnecessary side effects and saving medical costs.
Several factors have been known as predictors of SVR in CHC patients, including viral factors [8] [9] [10] [11] [12] [13] , host factors [14] [15] [16] [17] , metabolic factors [18] [19] [20] , histological factors [21] , the type of regimens [3] , the duration of infection [22, 23] and host genetic variations [24] [25] [26] [27] [28] .
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Introduction
Of note, the substitutions of amino acid (aa)70 and/or aa91 in the HCV core region (HCV-CR) has been identified as an independent and significant negative predictor of SVR to PEG-IFN plus RBV therapy in Japanese patients with HCV-1 infection [29, 30] . However, its predictive value in non-Japanese patients and association with other clinical factors in non-Japanese populations remain unclear and deserve further investigations.
To this end, we enrolled 147 consecutive treatmentnaive Taiwanese HCV-1 patients receiving combination therapy of PEG-IFN plus RBV and evaluated the effect of substitutions of aa70 and/or aa91 in the HCV-CR as well as its association with clinicopathological features.
Methods

Patient selection
A total of 147 treatment-naive CHC patients with HCV-1 infection from the gastroenterological clinics of the National Taiwan University Hospital and the National Taiwan University Hospital Yun-Lin Branch were enrolled as previously reported [7] . These patients had completed either 24 or 48 weeks of PEG-IFN plus RBV therapy and agreed with written informed consent to participate in the present study. All patients fulfilled the following criteria: age >18 years, presence of anti-HCV antibody and a detectable serum HCV RNA level determined by real-time PCR analysis for >6 months, HCV-1 infection confirmed by a reverse hybridization assay, serum alanine aminotransferase (ALT) level greater than the upper limit of normal, and histological characteristics consistent with chronic viral hepatitis within the previous 3 months.
Patients were excluded if they had anaemia (haemoglobin level <13 gm/dl for men and <12 gm/dl for women), neutropaenia (neutrophil count <1,500 cells/ mm 3 ), thrombocytopaenia (platelet count <70,000 cells/ mm 3 ), mixed infection with HCV-1 and other HCV genotype(s), coinfection with HBV or HIV, decompensated cirrhosis (Child-Pugh class B or C), serum creatinine level >1.5× the upper limit of normal, autoimmune liver disease, inheritable disorders such as haemochromatosis or Wilson's disease, neoplastic disease, organ transplantation or immunosuppressive therapy, evidence of drug abuse, pregnancy, poorly controlled autoimmune disease, cardiopulmonary disease, neuropsychiatric disorders, diabetes mellitus with retinopathy, a history of excess alcohol intake (daily alcohol consumption >20 g/ day) or active drug abuse, or unwillingness to receive contraception during the study period.
Study design
The study was performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice, was approved by the Ethical Committee of the National Taiwan University Hospital, and all patients gave informed consent of the present study before enrolment. All patients were randomized to receive either 24 or 48 weeks of weekly subcutaneous injections of 180 mg of PEG-IFN-α2a (Pegasys ® ; F Hoffman-LaRoche, Basel, Switzerland) and daily weight-based oral RBV (Copegus ® ; F HoffmanLaRoche; 1,000 mg per day for patients who weighed <75 kg and 1,200 mg per day for patients who weighed ≥75 kg) [7] . Participants received outpatient visits and the study drugs on an outpatient basis at weeks 1, 2, 4, 6, 8, and then every 4 weeks for a total period of 24 or 48 weeks and were then followed up monthly for an additional 24 weeks without therapy.
Information on sex, age, body mass index (BMI), serum fasting blood glucose, triglyceride, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), fasting insulin, albumin, aspartate aminotransferase (AST), ALT, γ-glutamyl transpeptidase (GGT) levels, and complete blood count and differential count were collected. BMI was calculated as weight in kg divided by height in m 2 . Pretreatment insulin resistance (IR) index was determined using homeostasis model assessment (HOMA-IR= fasting insulin [mU/l] × fasting glucose [mg/dl]×0.05551/22.5) [31] [32] [33] . Baseline blood samples were collected in the morning after 12 h fasting and measured by standard laboratory techniques. Hepatitis B surface antigen and anti-HCV were assayed with commercial kits (Abbott Laboratories, North Chicago, IL, USA). Serum HCV RNA levels were evaluated quantitatively by real-time PCR analysis (Cobas TaqMan HCV Test, version 2.0; Roche Diagnostics, Pleasanton, CA, USA; limit of detection 25 IU/ml) at baseline, week 4, week 12, the end of treatment and 24 weeks after the end of treatment. HCV genotyping was performed at baseline by a reverse hybridization technique (Inno-LiPA HCV II; Innogenetics, Ghent, Belgium). Patients with HCV-1 infection who received 48 weeks of treatment had an additional HCV RNA test performed at week 24 of treatment. All the remnant serum samples collected from each patient were stored at -80°C until use.
Histological evaluations of liver biopsy specimens
After written informed consent was given, each patient without contraindication for liver biopsy received an echo-guided percutaneous liver biopsy from the right hepatic lobe by using a 16-gauge Temno Evolution biopsy needle (Allegiance, McGaw Park, IL, USA). All biopsy specimens were fixed with formalin, embedded with paraffin, stained with haematoxylin and eosin as well as reticulin silver (Masson trichome method) and assessed by one experienced pathologist who was blinded to the clinical status of each patient. The staging of hepatic fibrosis was scored by the Metavir system, which ranged from F0 to F4 [34] . In brief, the stages of fibrosis were defined as follows: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. Brunt's recommendations were used to categorize hepatic steatosis and centrilobular fibrosis [35] . The classification of hepatic steatosis was as follows: grade 0, no steatosis; grade 1, between 0 and 33% of hepatocytes contained visible macrovesicular steatosis; grade 2, between 34 and 66%; and grade 3, >67%.
Assessment of efficacy
The definitions of virological responses to treatment were as follows. Rapid virological response (RVR) was defined as an undetectable serum HCV RNA level (<25 IU/ml) at week 4 of therapy. Early virological response (EVR) was defined as at least a 2-log reduction in serum HCV RNA level from baseline to week 12 of therapy. Complete EVR (cEVR) was defined as an undetectable serum HCV RNA level at week 12 of therapy in patients who did not achieve RVR, and partial EVR (pEVR) was defined as ≥2-log reduction in serum HCV RNA level from baseline to week 12 of therapy in those who did not achieve RVR at week 4 and did not achieve an undetectable serum HCV RNA level at week 12 of therapy. Non-virological response (NR) was defined as <2-log reduction in serum HCV RNA level from baseline to week 12 of therapy. End-of-treatment virological response and SVR were defined as an undetectable serum HCV RNA level at the end of treatment and at the end of follow-up, respectively.
The primary efficacy end point was SVR rate by intention-to-treat analysis. Patients who did not have data available at the end of follow-up were considered as not having achieved SVR. Treatment was prematurely discontinued in patients who were randomized to 48 weeks of treatment but continued to have HCV viraemia at week 24 of therapy, because they were not likely to achieve SVR with continued therapy.
Determination of aa sequences in the HCV-CR
HCV RNA was extracted from 140 ml of stored serum samples by using a commercial kit (QIAamp RNA Blood Mini Kit; Qiagen Inc., Valencia, CA, USA), and dissolved in 60 ml of H 2 O and then converted to complementary DNA (cDNA) by reverse transcription with the random primers and SuperScript™ II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The cDNA was then amplified by nested PCR to determine the nucleotide sequences in the HCV core region. The PCR protocol was initial denaturation at 95°C for 5 min, 35 cycles of denaturation for 30 s at 94°C, annealing of primers for 1 min at 57°C and extension for 1 min at 72°C, followed by final extension at 72°C for 7 min. The primers for the first-round PCR were cc11 (forward, 5′-GCC ATA GTG GTC TGC GGA AC-3′) and e14 (reverse, 5′-GGA GCA GTC CTT CGT GAC ATG-3′), and the primers for the second-round PCR were cc9 (forward, 5′-GCT AGC CGA GTA GTG TT-3′) and e14 (reverse) as previously described [36] . After amplification, the final PCR products were separated in 2% agarose gel and purified with the QIAquick gel extraction kit (Qiagen GmbH, Hilden, Germany). Sequence analysis was performed by ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Nucleotide sequences of the PCR products were then compared with those of HCV-J, a genotype 1b strain (GenBank accession number D90208), and the putative aa sequences were derived.
To analyse the relationship between aa substitutions in HCV-CR, the substitution of core aa70 (R70Q/ Y/H) and core aa91 (L91M) were divided into four groups as follows: coreMM, patients with both aa70 and aa91 substitutions; coreMW, those with only an aa70 substitution; coreWM, those with only an aa91 substitution; and coreWW, those without both aa70 and aa91 substitutions.
Statistical analyses
The data were presented as frequency and percentages for categorical variables and mean with standard deviations for continuous variables unless mentioned otherwise. Log transformation was performed for variables with significant deviation from normal distribution. The χ 2 test, Fisher's exact probability test, Mann-Whitney U test, Student's t-test or Wilcoxon's tests were used to analyse categorical, parametric continuous and non-parametric variables as appropriate. Unadjusted and adjusted OR and 95% CI as well as P-values were estimated for each variable by logistic regression. Stepwise estimation with forward-selection logistic regression model was used to evaluate the association between the substitutions of aa70 and/or aa91 in the HCV-CR and various clinicopathological features. The substitutions of aa70 and/or aa91 in the HCV-CR were the reference and dependent variable, and age, sex, waist circumference, BMI, fasting blood glucose, HOMA-IR, baseline HCV RNA level, triglyceride, total cholesterol, LDL, HDL, AST, ALT, GGT levels, Metavir activity, Metavir fibrosis, steatosis and platelet level were all included as independent variables. Using similar stepwise logistic regression analysis (forward), we examined the association between SVR and various clinical factors. SVR was used as a dependent variable, and age, sex, BMI, albumin, fasting blood glucose, HOMA-IR, triglyceride, platelet level, Metavir fibrosis stage, PEG-IFN treatment duration, RVR, EVR and core gene polymorphism were all used as independent variables. A P-value ≥0.2 was the significance level for removal from the model, and a P-value <0.1 was the significance level for addition to the model. Finally, several different models were constructed for predicting SVR and ranked according to their Akaike Information Criterion (AIC). The one having the lowest AIC was selected. All analyses were performed with Stata statistical software (version 8.0; Stata Corp., College Station, TX, USA). All tests were two-sided and a P-value of <0.05 was considered statistically significant.
Results
Demographic, biochemical, virological and histological characteristics
Demographic and biochemical characteristics of the study population are shown in Table 1 . Demographic and biochemical characteristics of the study population with and without sustained virological response Data are shown as mean ±sd, case number (%) or case number alone. HCV RNA level (IU/ml) is log 10 transformed for its significant deviation from normal distribution. Histological data were evaluated semi-quantitatively using the Metavir scoring system. Brunt's recommendation was used to grade hepatic steatosis. a There was 1 patient without available data of fasting serum albumin, 1 patient without triglyceride level, 12 patients without high-density lipoprotein (HDL) and 13 patients without low-density lipoprotein (LDL).
b
Only 120 patients had available fasting insulin data. c There were two patients without available data of hepatic steatosis and one without hepatic inflammatory activity score. P<0.05 was considered as statistically significant. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; cEVR, complete early virological response; coreMM, patients with both amino acid (aa)70 and aa91 substitutions in the core region; coreWW, patients without both aa70 and aa91 substitutions in the core region. EVR, early virological response; GGT, γ-glutamyl transpeptidase; HOMA-IR, insulin resistance index determined by homeostasis model assessment; PEG-IFN, pegylated interferon; pEVR, partial early virological response; RBV, ribavirin; RVR, rapid virological response.
Among 90 patients who achieved RVR, 61 had aa70 in the HCV-CR as R, 23 with core aa R70Q, 6 with core aa R70H, 52 had core aa91 as L and 38 with core aa L91M.
There were 48 patients who achieved cEVR. Among them, 28 had core aa70 as R, 18 with core aa R70Q, 2 with core aa R70H, 30 had core aa91 as L and 18 with core aa L91M. Of the 4 patients who achieved pEVR, 3 had core aa70 as R, 1 with core aa R70Q and 4 had core aa91 as L, but none with core aa R70H or L91M. For the 5 patients who were NR, 2 had core aa70 as R, 3 with core aa R70Q, 3 had core aa91 as L and 2 with core aa L91M. In addition, patients with HCV coreWW infection had similar NR rates to IFN-based treatment to those with HCV coreMM infection (coreWW 2/61 versus coreMM 2/20; P=0.229).
Of 97 patients who achieved SVR, 66 had core aa70 as R, 25 with core aa R70Q, 6 with core aa R70H, 60 had core aa91 as L and 37 with core aa L91M. Moreover, patients with HCV coreWW infection had higher SVR rates to interferon-based treatment than those with HCV coreMM infection ( Table 2 shows the demographic, biochemical, virological and histological characteristics of our patients with different aa substitutions in the HCV-CR. Compared with patients with coreWW, those with coreMM had a lower SVR rate, higher GGT level and more severe liver fibrosis. Patients with substitutions at aa70 in the HCV-CR (coreMW) had more severe liver steatosis and fibrosis than those without (Table 2) .
Association of amino acid substitutions in the HCV-CR with clinicopathological features
Multivariate analyses with stepwise approaches were used to examine the association between aa substitutions in the HCV-CR with various clinicopathological features (see section on Statistical analyses). The analyses showed that wild-type HCV core aa70 (R) was significantly associated with milder liver fibrosis than mutant-type HCV core aa70 (Q or H; P=0.026), and coreWW was associated with a lower serum HDL level than non-coreWW (P=0.017; Table 3 ).
Amino acid substitutions in the HCV-CR as a predictor of SVR
In univariate analyses, male gender, higher albumin level and platelet count, lower fasting blood glucose and triglyceride level, patients who received higher average dose of RBV, 48 weeks of combination therapy, presence of RVR or EVR, HCV coreWW infection or milder pretreatment hepatic fibrosis stage were significantly associated with SVR (Table 1) .
Multivariate analyses with stepwise approaches were used to examine the association between various clinicopathological features. The results showed that lower BMI, milder pretreatment hepatic fibrosis stage, 48 . ALT, alanine aminotransferase; BMI, body mass index; coreMM, patients with both amino acid (aa)70 and aa91 substitutions in the core region; coreMW, patients with only an aa70 substitution in the core region; coreWM, patients with only an aa91 substitution in the core region; GGT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein cholesterol; HOMA-IR, insulin resistance index determined by homeostasis model assessment; LDL, low-density lipoprotein cholesterol; RVR, rapid virological response; SVR, sustained virological response.
weeks of combination therapy or the presence of RVR were significantly associated with a higher SVR rate (Table 4 and Additional file 1, Model 1). However, the power of aa substitutions in the HCV-CR for predicting SVR seemed to be masked by these clinicopathological factors (Table 4 , Model 2 and Additional file 1, Models 2-5). We also performed subanalyses on these patients by categorized age, gender, BMI, duration of treatment or RVR to adjust the effects of these clinicopathological factors and determined the effect of aa substitutions in the HCV-CR to predict SVR, and the results remained unchanged (Additional file 1-7).
Discussion
Knowledge regarding the influence of various factors on spontaneous or treatment-induced HCV clearance helps us understand more about the natural history as well as the pathogenesis of this important viral infection, and also plays a key role in the development of personalized medicine. In this study, we initially identified several factors, including the substitutions of aa70 and/or aa91 in the HCV-CR, as candidates to predict the virological responses to PEG-IFN plus RBV therapy by using univariate analyses. However, the predictive power remained statistically effective only in BMI, duration of treatment, severity of liver fibrosis and RVR after adjustment for possible covariates and confounders. These lines of evidence suggested that the effect of aa substitutions in the HCV-CR on virological responses in HCV-1 patients may be outweighed by these clinicopathological factors. Nevertheless, we still demonstrated a close link among GGT level, severity of liver steatosis/fibrosis and aa substitutions in the HCV-CR, implying possible interactions of aa substitutions in the HCV-CR with histological characteristics to affect virological responses.
First, in univariate analyses, we found that male gender, lower BMI, lower fasting blood glucose and triglyceride level, higher serum albumin level and platelet count, milder degree of liver fibrosis, wild-type HCV core aa70 and 91, 48 weeks of treatment, and the presence of RVR and EVR were factors associated with a higher likelihood of attaining SVR to PEG-IFN plus RBV treatment in Taiwanese HCV-1 patients. Most of these factors are known to predict SVR, indicating a universal influence of these factors on SVR among different HCV genotypes. However, the associations of fasting serum insulin, GGT level, HOMA-IR index or the average dose of RBV with SVR were marginally significant. These observations could be explained by the Table 3 . Multivariate analyses identifying factors associated with different core gene polymorphisms
Stepwise estimation with forward-selection logistic regression model was used. Core gene polymorphisms (that is, wild type=0, such as wild-type HCV core aa70 [R] or coreWW) were used as the reference and dependent variable. Histological data were evaluated semi-quantitatively using the Metavir scoring system. Brunt's recommendation was used to grade hepatic steatosis. coreWW, patients without both aa70 and aa91 substitutions in the core region.
Core aa70 R versus non-R (n=135)
Non Histological data were evaluated semi-quantitatively using the Metavir scoring system. a P<0.05 was considered as statistically significant. coreMM, patients with both amino acid (aa)70 and aa91 substitutions in the core region; coreWW, patients without both aa70 and aa91 substitutions in the core region.
use of weight-based RBV, the coexistence of stronger covariates (for example, fasting blood glucose versus insulin or HOMA-IR index, or liver fibrosis versus GGT), the combination of data from patients receiving either 24 weeks or 48 weeks of treatment or a lower effect of these factors on HCV-1 infection.
In addition to the confirmation of aa substitutions in the HCV-CR to predict SVR, we further examined the associations of aa substitutions in the HCV-CR with other host or viral factors (Table 2 ). Our data showed that although patients with wild-type HCV core aa70 and 91 infection had better SVR and RVR rates than those with mutant-type HCV core aa70 and 91 infection, only the difference in SVR rates attained statistical significance (P=0.039). Of particular note is that aa substitution at position 70 with or without aa substitution at position 91 in the HCV-CR was significantly associated with a higher GGT level and more severe liver steatosis/fibrosis. Such an association between aa substitution at position 70 and the severity of liver fibrosis remained significant even after adjustment for possible covariates and confounders, implying a possible interaction between aa substitutions in the HCV-CR and clinicopathological factors. Moreover, HCV core proteins may regulate distinct biological functions in hepatic stellate cells. A direct interaction between HCV proteins and hepatic stellate cells has been implied to explain HCV-induced liver fibrosis [37] . Whether aa substitutions in HCV-CR play an important role in this interaction remains unclear and deserves further examinations.
Because aa substitutions in the HCV-CR might interact with clinicopathological factors, we therefore explored the association of aa substitutions in the HCV-CR with SVR by different models adjusted for possible covariates and confounders (Table 4 and Additional files [1] [2] [3] [4] [5] [6] . According to the model selected by AIC, Model 2 seemed to be the most appropriate model for the prediction of SVR, and RVR was the most important factor predictive of SVR. In addition, we found that the predictive power of core 70/91 mutations was outweighed by the stage of liver fibrosis when comparing Models 4 and 5, and became insignificant in Models 2 and 3. Therefore, except for aa substitutions in the HCV-CR, BMI, treatment duration and severity of liver fibrosis also serve as potent predictors of SVR in HCV-1 patients treated with combination therapy (Model 1). Moreover, Models 4 and 5 identified an important modifying effect of liver fibrosis on the association between aa substitutions in the HCV-CR and SVR. It is known that liver fibrosis is a predictor of SVR [21] , and several factors are related to [38] or served as surrogate markers of liver fibrosis [39] . The distorted architecture of hepatic lobules during the process of fibrogenesis may decrease the contact between hepatocytes and drugs, leading to the impairment of therapeutic efficacy [29] . Taken together, our modelling not only validates the importance of liver fibrosis in modulating therapeutic responses, but also indicates the predictive effect of aa substitutions in the HCV-CR could be affected by the severity of liver fibrosis, suggesting aa substitutions in the HCV-CR may contribute to the severity of liver histology, or through not yet identified mechanisms. Further studies are needed to address this interesting and important issue.
Several limitations existed in this study. First, this study was a cohort design with a total study period of 1.5 years. However, many histological changes become apparent after years of follow-up, and hence we only found the association between aa70 and/or aa91 in the HCV-CR and liver fibrosis stage. Further studies with a longitudinal study design and controls are required to elucidate possible causal relationships. A previous study demonstrating a particular link between aa70 and/or aa91 in the HCV-CR and hepatocellular carcinoma indeed shed some light on our speculation [40] . Second, our results confirmed the current concept that early viral kinetics is the most important predictor of SVR in CHC patients receiving IFN-based therapy than other baseline factors [41] . In Model 2, the most appropriate model to predict SVR, only RVR is the significant predictor of SVR. Therefore, if RVR is included into the multivariate models, other baseline predictors such as aa substitutions of HCV core 70 and 91 will be outweighed, and discrepant results from previous reports may ensue. However, if the sample size becomes larger, aa substitutions of HCV-CR and other baseline factors may become significant in the analyses. Third, the genetic variations of interleukin (IL)-28B, a recently identified predictor of SVR [24] [25] [26] [27] [28] , are not included in our study because this domain of knowledge was not available during the period of our study (June 2006 to March 2008 . Therefore, most of our patients had no available genomic DNA samples to determine single nucleotide polymorphisms related to IL-28B. Future studies to delineate the interactions between aa substitutions in the HCV-CR and genetic variations of IL-28B are warranted. Finally, a cross-validation study to verify the predictors of SVR is desirable and should be performed in the future.
In conclusion, wild-type HCV core aa70 and 91 is a negative predictor of SVR to IFN-based therapy in Taiwanese patients with HCV-1 infection, and wildtype HCV core aa70 with or without wild-type HCV core aa91 is associated with more advanced liver fibrosis stage. However, on-treatment virological responses have higher predictive values for SVR than other baseline factors. All these lines of evidence convey the information on the possible interaction between aa substitutions in HCV-CR and liver fibrosis, and justify the usefulness of a simplified model to predict SVR with on-treatment HCV RNA levels.
